PAIN MANAGEMENT Patient established on oral morphine or opioid naive.

Similar documents
PAIN MANAGEMENT Person established taking oral morphine or opioid naive.

PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT

Supporting Last Days of Life Symptom Control Medication Guidance: Algorithm. Agitation & Anxiety

Care of the Dying. For dosing in severe renal impairment see separate guidance for care of the dying in severe renal failure.

MMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life

Care of the Dying Management in Severe Renal Failure

ANTICIPATORY PRESCRIBING FOR PATIENTS AT END OF LIFE WITH RENAL IMPAIRMENT

Care of the Dying Management in Severe Renal Failure

Anticipatory Medications for End of Life Patients. Doses must be proportional to the current analgesic medication YES NO YES NO

Renal Prescribing at End of Life Guidance for Anticipatory prescribing for patients in renal failure (egfr<30) at the end of life

Symptom Management Guidelines for End of Life Care

PAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE

Algorithms for Symptom Management. In End of Life Care

[Type text] Anticipatory Medication STAT dose and Syringe Driver Guidance [Type text]

End of life prescribing guidance

Supportive Care. End of Life Phase

EAST LANCASHIRE GUIDELINES FOR THE MANAGEMENT OF SYMPTOMS IN THE LAST DAYS OF LIFE

PENNINE LANCASHIRE GUIDELINES FOR THE MANAGEMENT OF SYMPTOMS IN THE LAST DAYS OF LIFE

Renal Palliative Care Last Days of Life

GUIDELINES FOR PRESCRIBING AT THE END OF LIFE FOR PATIENTS WITH RENAL IMPAIRMENT (estimated glomerular filtration rate<30)

Care in the Last Days of Life

Syringe driver in Palliative Care

SYRINGE DRIVER MEDICATIONS

SYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL

For patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.

GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS

ALLERGIES/ SENSITIVITIES This section must be completed before prescribing/administering any drug

Palliative care for heart failure patients. Susan Addie

Diamorphine 4 hour. alfentanil (500microgram/mL) Calculated by dividing 24 hour oral morphine dose by 30

Anticipatory prescribing and end of life considerations. Dr Stephanie Lippett

INTEGRATED CARE PATHWAY (ICP) FOR THE DYING ADULT

Care of dying adults in the last days of life. Improving care at the very end of life.

Analgesia. This is widely used in palliative care. It has antipyretic and analgesic effects but no anti-

SUBCUTANEOUS AS REQUIRED & SYRINGE PUMP PRESCRIPTION & ADMINISTRATION RECORD (SPAR) Name: Address: Postcode: Date of Birth: NHS Number:

Doncaster & Bassetlaw Cancer Locality. Palliative Care Core Formulary

Conservative Management of Uraemia

Guidelines: EOLC Symptom Control for Patients with Normal Renal Function (in Wandsworth)

End Stage Liver Disease Regional Audit Casenote Survey

SYMPTOM CONTROL IN THE LAST DAYS OF LIFE. Bradford, Airedale, Wharfedale & Craven

Waterloo Wellington (WW) Symptom Management Guideline for the End of Life (EOL) Medication Order Set for Long Term Care (LTC)

Implementing the recommendation on medication management and symptom control

1. GUIDELINES FOR THE MANAGEMENT OF AGITATION IN ADVANCED CANCER

Palliative Care Out-of-hours. A resource pack for West Dorset. Contents:

Palliative Care Impact Survey

Coversheet for Network Site Specific Group Agreed Documentation

Palliative Prescribing - Pain

Managing Respiratory Symptoms - Breathlessness, Cough and Secretions. Dr Laura Healy. Palliative Medicine Registrar, Beaumont Hospital.

End of Life Care. Dr Anne Garry Consultant in Palliative Medicine

Syringe Drivers. Back to top

The last days of life in hospital and at home

BJF Acute Pain Team Formulary Group

This survey aims to look at individual practice and can be completed by any healthcare professional.

MND Just in Case kit Information for GPs

Essential Syringe Driver Training for T 34. Elaine Bird St Luke s Hospice

Using syringe pumps in palliative care

Mid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care

Understanding pain in 5 minutes

We would like to thank you for completing this audit questionnaire which looks at how you manage nausea and vomiting in palliative care patients.


Berkshire Adult Palliative Care Guidelines - End of Life Care GL110

Regional Renal Training

Palliative Care Formulary

Pain management in Paediatric Palliative Care. Dr Jane Nakawesi 14 th August 2017

BREATHLESSNESS MANAGEMENT

Target audience: The target audience for this guidance are: GPs Care home managers and nurses, District nurses, and Specialist Palliative Care teams.

Clatterbridge Centre for Oncology

Respiratory Secretions. Care in the last 72 hours of life Paul Tait, pharmacist

Approach to symptom control near the end-of-life

Lothian Palliative Care Guidelines POCKET EDITION 2004

Planning for the future; A guide to symptom control at end of life in advanced dementia

Agitation. Susan Emmens Palliative Care Clinical Nurse Specialist

Eastern Health and Social Services Board Palliative Care

BACKGROUND Measuring renal function :

Palliative Care. Pocketbook 4

CARE OF THE DYING PATIENT WITH ESKD ELIZABETH JOSLAND - RSC CNC

1 (ix) Pain control. What responsibilities do you assume when you prescribe analgesia?

Palliative Care. Anticipatory Prescribing Guidelines & June Gippsland Region Palliative Care Consortium Clinical Practice Group

Policy/Standard Operating Procedure/ Clinical Guideline. ELHT/CP22 Version 5.1. ELHT/CP22 Version 4.1

NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES

Symptom Control in the Community Setting. Dr Andrew Tysoe-Calnon

Pain management in palliative care. Dr. Stepanie Lippett and Sister Karen Davies-Linihan

East Kent Prescribing Group

General Palliative Care Guidelines for the Management of Pain at the End of Life in Adult Patients

Prescribing Examples: Basics

GG&C Chronic Non Malignant Pain Opioid Prescribing Guideline

Palliative care for patients with brain cancer

PALLIATIVE CARE PRESCRIBING

PHARMACY SERVICE ARRANGEMENTS FOR THE SUPPLY OF PALLIATIVE CARE SYRINGES AND MEDICINES FOR COMMUNITY PATIENTS

CLINICAL GUIDELINES FOR END OF LIFE CARE MEDICATIONS IN LONG TERM CARE HOMES

What s New 2003? What new treatments? What have you discontinued? More information please!

Opioid rotation or switching may be considered if a patient obtains pain relief with one opioid and is suffering severe adverse effects.

PALLIATIVE CARE PRESCRIBING

GUIDELINES AND AUDIT IMPLEMENTATION NETWORK

A Brief Guide to Symptom Management and End of Life Care for Children During Pandemic Influenza

Treating the symptoms of kidney failure

Long Term Care Formulary HCD - 08

Overview of Essentials of Pain Management. Updated 11/2016

Opioid Conversion Guidelines

PCA PRESCRIPTION is valid for a maximum of 4 days unless ceased earlier. Date: BINDING MARGIN - NO WRITING BINDING MARGIN - NO WRITING

Palliative Care and the Critical Role of the Pharmacist. Arti Thakerar Education/ Palliative Care Peter MacCallum Cancer Centre

Transcription:

PAIN MANAGEMENT Patient established on oral morphine or opioid naive. Important; It is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member of the team has a responsibility to check that the intended dose is safe for the individual patient. Knowledge of previous opioid dose is essential for the safe use of these products. Advice should be sought if prescribing outside of these guidelines or when the limits of own expertise are reached (NPSA/2008/RRR05) CONTACT THE PALLIATIVE CARE TEAM (Details below) FOR ADVICE IF: The patient has moderate to severe renal failure. The patient has new severe pain or pain that has persisted after 24 hours on a syringe driver. YES PATIENTS IS TAKING ORAL MORPHINE NO Stop all oral Morphine Convert total daily dose of oral Morphine to subcutaneous route by dividing by 2 and prescribe this dose subcutaneously via a syringe driver over 24 hours (see example (a) below). Prescribe a breakthrough pain dose of Morphine that is 1/6 th of the calculated total Morphine dose IN SYRINGE DRIVER, SC hourly PRN (see example (b) below). Reassess after 24 hours. If patient has required additional Morphine for breakthrough pain calculate total dose given over 24 hours and increase dose in syringe driver by 50% of this amount. Ensure breakthrough dose remains at 1/6 th of syringe driver dose. YES Patient has pain Prescribe and give Morphine 2.5 mg-5 mg SC STAT Prescribe Morphine 10 mg via syringe driver over 24 hours Prescribe Morphine 2.5-5 mg SC PRN hourly for breakthrough pain. Reassess after 24 hours NO Prescribe in anticipation of symptom Morphine 2.5 mg-5 mg SC PRN hourly Example (a) syringe driver dose Converting from oral Morphine to syringe driver e.g. Zomorph 60 mg 12 hourly = 120 mg 120mg/2 = 60 mg Dose of Morphine subcutaneously via syringe driver over 24 hours = 60 mg Example (b) calculating breakthrough dose The breakthrough dose is 1/6 th of total daily morphine dose e.g. Patient requires 60 mg Morphine via syringe driver over 24 hours 60/6 = 10 mg Morphine SC PRN 1

PAIN MANAGEMENT Patients established on Fentanyl Patches Important; It is the responsibility of the presriber to ensure that guidelines are followed when prescribing opioids. Every member of the team has a responsibility to check that the intended dose is safe for the individual patient. Knowledge of previous opioid dose is essential for the safe use of these products. Advice should be sought if prescribing outside of these guidelines or when the limits of own expertise are reached (NPSA/2008/RRR05) DO NOT COMMENCE FENTANYL PATCHES FOR PAIN RELIEF IN THE DYING PHASE. If the patient has severe renal dysfunction and requires additional pain relief seek advice on prescribing from the palliative care team. FENTANYL ESTABLISHED PAIN PRESENT DO NOT remove Fentanyl Patch continue and re-apply every 72 hours. PAIN CONTROLLED Prescribe opioid for breakthrough pain as needed. As table below. Prescribe adequate dose of breakthrough opioid analgesia as table below. Re-asses after 24 Hrs If 2 or more doses of breakthrough opioid are required in 24 hrs commence syringe driver. Prescribe 50% of the total amount of breakthrough given in previous 24hrs via syringe driver in addition to Fentanyl patch. OBTAIN SPECIALIST PALLIATVE CARE ADVICE REGARDING CALCULATING SUBSEQUENT PRN DOSE OF OPIOID S/C ONCE OPIOID IS REQUIRED IN SYRINGE DRIVER. Fentanyl Patch strength Up to hourly Morphine sc PRN Up to hourly Oxycodone sc PRN 12 micrograms per hour 2.5 mg 1.25mg 2.5mg 25 micrograms per hour 5 mg 2.5 mg 50 micrograms per hour 10 mg 5 mg 75 micrograms per hour 20 mg 10 mg 2

PAIN MANAGEMENT For patients established on oral Oxycodone Important it is the responsibility of the presriber to ensure that guidelines are followed when prescribing opioids. Every member of the team has a responsibility to check that the intended dose is safe for the individual patient. Knowledge of previous opioid dose is essential for the safe use of these products. Advice should be sought if prescribing outside of these guidelines or when the limits of own expertise are reached (NPSA/2008/RRR05) BOTH 3:2 AND 2:1 CONVERSIONS FROM ORAL OXYCODONE TO THE SUBCUTANEOUS ROUTE ARE USED. IN THE DYING PHASE USE 3:2 AS BELOW CONVERT ORAL OXYCODONE TO SUBCUTANEOUS ROUTE AS BELOW CALCULATE DOSE REQUIRED OVER 24 HOURS IN SYRINGE DRIVER: SYRINGE DRIVER DOSE = 2/3 OF ORAL DAILY DOSE. e.g. Oxycontin 45 mg 12 hrly = 90 mg 2/3 of 90 mg = 60 mg dose required in syringe driver = 60 mg CALCULATE DOSE OF OXYCODONE REQUIRED FOR RELIEF OF BREAKTHROUGH PAIN. BREAKTHROUGH DOSE = 1/6 TH DOSE IN SYRINGE DRIVER. e.g. Oxycodone 60 mg/24 hours in syringe driver = 10 mg Oxycodone SC PRN RE-ASSESS AFTER 24HRS if patient has required breakthrough analgesia calculate total amount given in previous 24 hrs and increase dose in syringe driver by 50% of this amount. ENSURE THAT BREAKTHROUGH DOSE REMAINS 1/6 th of DOSE IN SYRINGE DRIVER 3

NAUSEA & VOMITING for patients without heart failure PRESENT ABSENT On anti-emetics Not on anti-emetics Prescribe Cyclizine 50mg SC stat dose and commence 150 mg/24 hours via syringe driver. Prescribe in anticipation of symptom Cyclizine 50 mg SC 8 Hourly PRN If symptoms persist ADD Haloperidol 1.5 mg 5 mg SC via syringe driver over 24 hours Seek advice via advice line number below CYCLIZINE IS NOT RECOMMENDED IN PATIENTS WITH HEART FAILURE. Alternative anti-emetics according to local policy & procedure may be prescribed, e.g. Haloperidol 1.5mg 3mg SC PRN max 10mg/24 hours. 1.5mg-5mg via a syringe driver over 24 hours Levomepromazine 6.25mg SC PRN 8 hourly or 6.25 mg 25 mg via a syringe driver over 24 hrs 4

TERMINAL RESTLESSNESS & AGITATION The intention of sedation in palliative care is to relieve distress unconsciousness may occur but is not a desired outcome (refer to NPSA/2008/RRR011) PRESENT ABSENT Urinary retention and rectal distension from constipation are common reversible causes of agitation ensure these are excluded. Prescribe Midazolam 2.5 mg 5 mg SC PRN until syringe driver commenced. If 2.5 mg ineffective after 30 minutes, give a further 5 mg (total 7.5 mg in 1 hour) If patient remains agitated seek medical review and contact Specialist Palliative Care Team for advice. If agitation likely to persist commence Midazolam 10 mg-20 mg SC via Syringe Driver over 24 hours. In addition prescribe Midazolam 2.5 mg-5 mg SC PRN up to hourly. Prescribe in anticipation of symptom Midazolam 2.5 mg 5 mg SC up to hourly PRN. Maximum 30 mg in 24 hours To calculate the subsequent subcutaneous dose of Midazolam over 24 hours: Calculate and add total dose of Midazolam given on a PRN basis over previous 24 hours to current 24 hour dose via syringe driver. Increase the dose of Midazolam accordingly up to 30 mg in syringe driver over 24 hours. Continue with PRN Midazolam calculate dose as 1/6 th of syringe driver dose. If Midazolam 30 mg in syringe driver is reached and symptoms are not controlled, please seek advice. 5

RESPIRATORY TRACT SECRETIONS It is important to start treatment as soon as symptoms occur PRESENT ABSENT Prescribe Glycopyrronium 200 micrograms SC STAT & Commence syringe driver containing Glycopyrronium 1200 micrograms over 24 hours. Prescribe in addition Glycopyrronium 200 micrograms 6 hourly prn (max dose 2400 micrograms in 24 hours) Prescribe Glycopyrronium 200 micrograms sc 6 hourly PRN (Max 2400 micrograms in 24 hrs) Prescribing in anticipation of this common symptom may prevent delay in commencing treatment. If respiratory tract secretions persist over the next 24 hours, increase Glycopyrronium to 2400 micrograms over 24 hours. This is a maximum dose. There is no benefit from additional PRN doses. NB- Hyoscine Hydrobromide can be used as an alternative use 400 micrograms SC as PRN dose and 1200 micrograms via syringe driver 6

DYSPNOEA YES DISTRESSING BREATHLESSNESS NO Prescribe Morphine 2.5 mg -5 mg SC 4 hourly PRN & Midazolam 2.5 mg SC 4 hourly PRN State on drug chart that indication is breathlessness Prescribe PRN opioids & anxiolytic in anticipation of symptom Morphine 2.5 mg SC 4 hourly PRN & Midazolam 2.5 mg SC 4 hourly PRN Or if breathlessness is constant Morphine 5 mg -10 mg via syringe driver over 24 hours (if previously taking oral opioid for breathlessness convert previous oral opioids dose) (see pain algorithm) & Midazolam 5 mg-10 mg via syringe driver over 24 hours. 7